Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1
- Conditions
- Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 68
- Registration Number
- NCT04984434
- Locations
- 🇨🇳
Shaohong Yin, Linyi, Shandong, China
A Phase â…¡ Study of F520 in Patients With Urothelial Carcinoma
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 80
- Registration Number
- NCT04636515
A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)
Phase 2
- Conditions
- Secondary Central Nervous System LymphomaPrimary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 43
- Registration Number
- NCT04457869
The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 105
- Registration Number
- NCT04457830
Phase â… Study to Evaluate the Safety and Tolerability of Using F520
Phase 1
- Conditions
- Advanced Solid Tumor，Recurrent Solid Tumor，Lymphoma，Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma
- Interventions
- Drug: Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 75
- Registration Number
- NCT03657381
- Locations
- 🇨🇳
Shaohong Yin, Linyi, Shandong, China
© Copyright 2025. All Rights Reserved by MedPath